Following presentation to the Aeronext scientific committee, the consortium has now received mid-term approval from the Walloon Region’s to continue and finalise this important project (4.863.844 € total amount).
The panel of international experts sitting on the jury notes that “the project remains very interesting and has strong industrial potential”.
Share this article on your networks to share it with your friends
Innovative inhalation pharmaceutical technology company Aquilon Pharma, based in Belgium, has signed a purchase order for ISAB’s high-precision R&D system...
Aquilon Pharma is a spin-off from the University of Liège set up at the end of 2013, specializing in the...
Canal Z « Aquilon Pharma inaugure son nouveau laboratoire » The 31/01/2022 by Maxime Simon. L’Echo « Aquilon démarre une...
With the support of Awex, Revatis, Brevo Motors, Aquilon Pharma and Taipro set up a joint representative office in Texas....
Aquilon Pharmaceuticals has passed an important milestone in the development of its first treatment AQ001S, based on a technological complex...
Following a decision, taken during the September Board meeting, Mr Paul Maes handed over the role of Executive Chairman to...
The BioWin-funded Aeronext research project has reached its mid-term milestone, confirming the clinical and technological potential of HP-Betadex formulations for...